West Pharmaceutical Services, Inc. - WST STOCK NEWS

West Pharmaceutical Services reported Q2 2022 net sales of $771.3 million, a 6.6% increase, with organic growth at 13.1%. Diluted EPS was $2.48, slightly up from $2.47 year-over-year. The company revised its full-year 2022 net sales guidance to $2.950-$2.975 billion from $3.050-$3.075 billion, citing a decline in COVID-19 related sales. Adjusted-diluted EPS guidance was also lowered to $9.00-$9.15. Proprietary Products showed robust growth, while Contract-Manufactured Products saw a 13.6% decline in sales.

West Pharmaceutical Services, Inc. (NYSE: WST) has elected Stephen Lockhart, M.D., Ph.D., to its Board of Directors, expanding the board to 11 members. Dr. Lockhart, a veteran physician and former Chief Medical Officer of Sutter Health, brings over 20 years of healthcare experience. His leadership background includes roles in quality, patient safety, and health equity advancements. West generated over $2.83 billion in sales in FY 2021 and boasts a global workforce of approximately 10,000 employees. This appointment is expected to enhance West's strategic direction in delivering innovative healthcare solutions.

West Pharmaceutical Services (NYSE: WST) will release its second-quarter 2022 financial results before the market opens on July 28, 2022. Following this, a conference call is scheduled for 9:00 a.m. Eastern Time to discuss the results and future business expectations. A live audio-only webcast will be accessible via the Company’s Investor Relations website. Participants can register in advance to pose questions during the call. A replay will be available for 30 days post-event. West is a leader in innovative injectable solutions, generating over $2.83 billion in sales in 2021.

West Pharmaceutical Services (NYSE: WST) has published its 2021 Corporate Responsibility Report, highlighting significant progress in environmental sustainability, diversity, and philanthropic efforts. Key achievements include the establishment of an ESG Steering Committee, an increase in waste diversion from landfills to 85%, and a 72% rise in employee giving. Notably, 64% of the Executive Team comprises women or U.S. minorities. The report aligns with global sustainability standards, reinforcing West's commitment to improving patient lives while managing its corporate responsibilities.

West Pharmaceutical Services (NYSE: WST) announced the launch of its new Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System at the BIO International Convention in San Diego, CA, from June 13-16, 2022. This advanced syringe system is an expansion of the existing 1mL version, designed to facilitate larger volume injections, thereby enhancing patient experience by potentially reducing the number of injections needed. The partnership with Daikyo allows for global distribution of this innovative product.

West Pharmaceutical Services (NYSE: WST) has been awarded the Biotech Innovation Award for its DeltaCube™ Modeling Platform at INTERPHEX 2022 in New York. This platform aids in container closure system (CCS) selection, optimizing drug development processes. Senior VP Chris Ryan emphasized its role in reducing risk and accelerating drug delivery to patients. The DeltaCube™ platform leverages over 90 years of experience to enhance vial integrity and troubleshoot defects efficiently. In 2021, West generated $2.83 billion in net sales, underscoring its position in the market.

West Pharmaceutical Services, a leader in injectable drug administration solutions, will participate in INTERPHEX 2022 on May 26, 2022. The company aims to showcase advancements in packaging technology, addressing industry challenges and trends. Notable presentations include a session on Novel Parenteral Packaging Components by experts Simon Cote and Eric Kurtz, highlighting innovations in fill-finish processing. Additionally, the DeltaCube™ Modeling Platform will be featured in a poster session by Anthony Bucci, visualizing component dimensional consistency. West generated $2.83 billion in net sales in 2021.

West Pharmaceutical Services (NYSE: WST) announced significant leadership changes on May 12, 2022. Bernard J. Birkett has been appointed Chief Financial and Operations Officer, expanding his role to include Global Operations and Supply Chain following David Montecalvo's resignation. Cindy Reiss-Clark is now Chief Commercial Officer, while Chris Ryan has been named Senior Vice President for Containment and Glass Systems. Kathy dePadua joins as Vice President and Chief Quality Officer, bringing extensive experience from GE Healthcare. These transitions aim to strengthen West's leadership in injectable drug administration.

West Pharmaceutical Services, a leader in injectable drug administration solutions, will participate in the Bank of America Securities 2022 Healthcare Conference from May 9-13 in Las Vegas, presenting on May 10 at 11:20 AM PDT. Additionally, the company will present at the 42nd Annual William Blair Growth Stock Conference in Chicago on June 6 and at the Jefferies Global Healthcare Conference in New York on June 9. A live audio webcast will be available on their website, with replays for 90 days. West reported $2.83 billion in net sales in fiscal year 2021.